Preparation and pharmacodynamics of stearic acid and poly (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles for 10-hydroxycamptothecin

International Journal of Pharmaceutics

Volumn 393, Issue 1-2, 2010, Pages 144-152

  Zhou, Yue Yu ^a,b   Du, Yong Zhong ^b   Wang, Ling ^b   Yuan, Hong ^b   Zhou, Jian Ping ^a   Hu, Fu Qiang ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

10 Hydroxycamptothecin; Anti tumor; Chitosan oligosaccharide; PLGA; Polymeric micelle; Stearic acid

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; 10 HYDROXYCAMPTOTHECIN; CARBOXYL GROUP; CARBOXYLIC ACID DERIVATIVE; CHITOSAN; DRUG CARRIER; LACTONE; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; STEARIC ACID; TRINITROBENZENESULFONIC ACID; WATER; 1 ETHYL 3 (3 (DIETHYLAMINO)PROPYL)CARBODIIMIDE; 1-ETHYL-3-(3-(DIETHYLAMINO)PROPYL)CARBODIIMIDE; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYANAMIDE; DRUG DERIVATIVE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; STEARIC ACID DERIVATIVE;

AQUEOUS SOLUTION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CHEMICAL REACTION; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; INTERNALIZATION; MICELLE; PH; PRIORITY JOURNAL; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG STABILITY; KINETICS; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHARMACEUTICS; SOLUBILITY; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CARBODIIMIDES; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; HEP G2 CELLS; HUMANS; HYDROPHOBICITY; KINETICS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; STEARIC ACIDS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77953476310     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.04.025     Document Type: Article

References (45)

1. Alexis K., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
2. Burke T.G., Mi Z. The structural basis of camptothecin interactions with human serum albumin impact on drug stability. J. Med. Chem. 1994, 37:40-46.
3. Carbonero R., Supko J.G. Current perspectives on the clinical experience,pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 2002, 8:641-661.
4. Cortesi R., Esposito E., Maietti A., Menegatti E., Nastruzzi C. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int. J. Pharm. 1997, 159:95-103.
5. Ertl B., Platzer P., Wirth M., Gabor F. Poly(d,l-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. J. Control. Release 1999, 61:305-317.
6. Guo R., Zhang L.Y., Jiang Z.P., Cao Y., Ding Y., Jiang X.Q. Synthesis of alginic acid-poly[2-(diethylamino)ethyl methacrylate] monodispersed nanoparticles by a polymer-monomer pair reaction system. Biomacromolecules 2007, 8:843-850.
7. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994, 12:53-63.
8. He X.G., Lu W., Jiang X.Q., Zhang X.W., Ding J. Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10-hydroxycamptothecins. Bioorg. Med. Chem. 2004, 12:4003-4008.
9. Hong J.W., Park J.H., Huh K.M., Chung H., Kwon I.C., Jeong S.Y. PEGylated polyethylenimine for in vivo local gene delivery based on lipiodolized emulsion system. J. Control. Release 2004, 99:167-176.
10. Hong M.H., Zhu S.J., Jiang Y.Y., Tang G.T., Pei Y.Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J. Control. Release 2009, 133:96-102.
11. Hu F.Q., Ren G.F., Yuan H., Du Y.Z., Zeng S. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf. B 2006, 50:97-103.
12. Hu F.Q., Wu X.L., Du Y.Z., You J., Yuan H. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin. Eur. J. Pharm. Biopharm. 2008, 69:117-125.
13. Hu F.Q., Zhao M.D., Yuan H., You J., Du Y.Z., Zeng S. A novel chitosan oligosaccharide-stearic acid micelles for gene delivery: properties and in vitro transfection studies. Int. J. Pharm. 2006, 315:158-166.
14. Kwon G.S., Okano T. Polymeric micelles as new drug carriers. Adv. Drug Deliv. Rev. 1996, 21:107-116.
15. Laco G.S., Collins J.R., Luke B.T., Kroth H., Sayer J.M., Jerina D.M., Pommier Y. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry 2002, 41:1428-1435.
16. Liu S.Q., Wiradharma N., Gao S.J., Tong Y.W., Yang Y.Y. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials 2007, 28:1423-1433.
17. Lu B., Zhang Z.Q. Novel colon-specific microspheres with highly dispersed hydroxycamptothecin cores: their preparation, release behavior, and therapeutic efficiency against colonic cancer. J. Pharm. Sci. 2006, 95:2619-2630.
18. Miwa A., Ishibe A., Nakano M., Yamahira T., Itai S., Jinno S., Kawahara H. Development of novel chitosan derivatives as micellar carriers of taxol. Pharm. Res. 1998, 15:1844-1850.
19. Morris J.D., Fernandez J.M., Chapa A.M., Gentry L.R., Thorn K.E., Weick T.M. Effects of sample handling, processing, storage, and hemolysis on measurement of key energy metabolites in ovine blood. Small Ruminant Res. 2002, 43:157-166.
20. Muggia F.M., Creaven P.J., Hansen H.H., Cohen M.H., Selawry O.S. Phase I clinical trials of weekly and daily treatment withcamptothecin. Cancer Chemother. Rep. 1972, 56:515-521.
21. O'Leary J., Muggia F.M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer 1998, 34:1500-1508.
22. Pourquier P., Pommier Y. Topoisomerase I-mediated DNA damage. Adv. Cancer Res. 2001, 80:189-216.
23. Rapoport N. Stabilization and activation of Pluronic micelles for tumor-targeted drug delivery. Colloid Surf. B: Biointerfaces 1999, 16:93-111.
24. Sahoo S.K., Panyam J., Prabha S., Labhasetwar V. Residual polyvinyl alcohol associated with poly(d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 2002, 82:105-114.
25. Schnurch A.B., Krajicek M.E. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates. J. Control. Release 1998, 50:215-223.
26. Shenderova A., Burke T.G., Schwendeman S.P. The acidic microelimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. 1999, 16:241-248.
27. Shenderova A., Burke T.G., Sehwendeman S.P. Stabilization of 10-hydroxycamptothecin in poly (lactide-co-glycolide) microsphere delivery vehicles. Pharm. Res. 1997, 14:1406-1414.
28. Shi B., Fang C., Pei Y.Y. Stealth PEG-PHDCA niosomes: effects of chain length of peg and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J. Pharm. Sci. 2006, 95:1873-1887.
29. Sun X., Wu F., Lu W., Zhang Z.R. Sustained-release hydroxycamptothecin polybutylcyanoacrylate nanoparticles as a liver targeting drug delivery system. Pharmazie 2004, 59:791-794.
30. Tahara K., Yamamoto K., Hirashima N., Kawashima Y. Chitosan-modified poly (d,l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur. J. Pharm. Biopharm. 2009, 10.1016/j.ejpb.2009.12.007.
31. Thomas C.J., Rahier N.J., Hecht S.M. Camptothecin: current perspectives. Bioorg. Med. Chem. 2004, 12:1585-1604.
32. Tsao Y.P., Russo A., Nyamuswa G., Silber R., Liu L.F. Interaction between replication forks and topoisomerase-I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 1993, 53:5908-5914.
33. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.T., Sim G.A. Plant antitumor agents. I. isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J. Am. Chem. Soc. 1966, 88:3888-3890.
34. Wang Y.Q., Li L.F., Jiang W., Larrick J.W. Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg. Med. Chem. 2005, 13:5592-5599.
35. Wani M.C., Ronman P.E., Lindley J.T., Wall M.E. Plant antitumor agents.18. Synthesis and biological activity of camptothecin analogues. J. Med. Chem. 1980, 23:554-560.
36. Yang L., Cui F.D., Cun D.M., Tao A.J., Shi K., Lin W.H. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int. J. Pharm. 2007, 340:163-172.
37. Yang R., Shim W.S., Cui F.D., Cheng G., Han X., Jin Q.R., Kim D.D., Chung S.J., Shim C.K. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int. J. Pharm. 2009, 371:142-147.
38. Zhang J.A., Xuan T., Parmar M., Ma L., Ugwu S., Ali S., Ahmad I. Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 2004, 270:93-107.
39. Zhang R.W., Li Y.F., Cai Q.Y., Liu T.P., Sun H., Chambless B. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerasc I. Cancer Chemother. Phammcol. 1998, 41:257-267.
40. Zhang L.Y., Sun M.J., Guo R., Jiang Z.P., Liu Y., Jiang X.Q., Yang C.Z. Chitosan surface-modified hydroxycamptothecin loaded nanoparticles with enhanced transport across Caco-2 cell monolayer. J. Nanosci. Nanotechnol. 2006, 6:2912-2920.
41. Zhang L.Y., Yang M., Wang Q., Li Y., Guo R., Jiang X.Q., Yang C.Z., Liu B.R. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J. Control. Release 2007, 119:153-162.
42. Zhang, C., Ding, Y., Liangli (Lucy), Yu, Ping, Q.N., 2007b. Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives. Colloids Surf. B: Biointerfaces 55, 192-199.
43. Zhang Y.D., Hu Z.Y., Ye M.Y., Pan Y.F., Chen J.J., Luo Y.L., Zhang Y.Q., He L.X., Wang J.W. Effect of poly(ethylene glycol)-block-polylactide nanoparticles on hepatic cells of mouse: low cytotoxicity, but efflux of the nanoparticles by ATP-binding cassette transporters. Eur. J. Pharm. Biopharm. 2007, 66:268-280.
44. Zhao Y.X., Gao J.Q., Sun X.Y., Chen H.L., Wu L.M., Liang W.Q. Enhanced nuclear delivery and cytotoxic activity of hydro-xycamptothecin using o/w emulsions. J. Pharm. Pharm. Sci. 2007, 10:61-70.
45. Zhou J.J., Liu J., Xu B. Relationship between lactone ring forms of HCPT and their antitumor activities. Acta Pharmacol. Sin. 2001, 22:827-830.